Capital Fund Management S.A. increased its position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 20.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 59,246 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,900 shares during the quarter. Capital Fund Management S.A. owned 0.39% of Eagle Pharmaceuticals worth $4,674,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. BNP Paribas Arbitrage SA lifted its stake in Eagle Pharmaceuticals by 15.0% during the first quarter. BNP Paribas Arbitrage SA now owns 1,548 shares of the specialty pharmaceutical company’s stock worth $128,000 after purchasing an additional 202 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in Eagle Pharmaceuticals by 78.9% during the second quarter. State of Alaska Department of Revenue now owns 1,592 shares of the specialty pharmaceutical company’s stock worth $125,000 after purchasing an additional 702 shares during the last quarter. Mason Street Advisors LLC lifted its stake in Eagle Pharmaceuticals by 10.2% during the first quarter. Mason Street Advisors LLC now owns 1,895 shares of the specialty pharmaceutical company’s stock worth $157,000 after purchasing an additional 175 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its stake in Eagle Pharmaceuticals by 6.7% during the second quarter. Municipal Employees Retirement System of Michigan now owns 1,910 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 120 shares during the last quarter. Finally, Bank of Montreal Can lifted its stake in Eagle Pharmaceuticals by 323.9% during the second quarter. Bank of Montreal Can now owns 2,497 shares of the specialty pharmaceutical company’s stock worth $197,000 after purchasing an additional 1,908 shares during the last quarter.

Shares of Eagle Pharmaceuticals, Inc. (EGRX) opened at 60.02 on Tuesday. Eagle Pharmaceuticals, Inc. has a 12 month low of $45.05 and a 12 month high of $97.15. The firm has a market capitalization of $910.44 million, a price-to-earnings ratio of 10.08 and a beta of 1.30. The firm has a 50-day moving average price of $54.25 and a 200 day moving average price of $74.11.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.51 by $0.18. The company had revenue of $50.10 million during the quarter, compared to analyst estimates of $52.52 million. Eagle Pharmaceuticals had a net margin of 39.32% and a return on equity of 66.30%. Eagle Pharmaceuticals’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.80 EPS. On average, analysts anticipate that Eagle Pharmaceuticals, Inc. will post $3.70 EPS for the current fiscal year.

Eagle Pharmaceuticals announced that its Board of Directors has approved a stock buyback plan on Wednesday, August 9th that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the specialty pharmaceutical company to reacquire up to 13.3% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

In related news, Director Douglas L. Braunstein purchased 20,400 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were acquired at an average price of $49.07 per share, with a total value of $1,001,028.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 19.50% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/12/eagle-pharmaceuticals-inc-egrx-shares-bought-by-capital-fund-management-s-a.html.

Several brokerages recently issued reports on EGRX. Piper Jaffray Companies set a $118.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, July 25th. Mizuho reduced their price objective on Eagle Pharmaceuticals from $40.00 to $37.00 and set an “underperform” rating on the stock in a research note on Wednesday, September 6th. BidaskClub cut Eagle Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, July 31st. Royal Bank Of Canada set a $94.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, July 16th. Finally, Zacks Investment Research cut Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, July 31st. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Eagle Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $74.80.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Stock Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.